Clascoterone for Acne: Four Trial Checks

A prescription discussion can start with the routine already on your bathroom shelf. Bring the products, their strengths and the dates you started them. Ask which one a new prescription would replace, which would stay, and how the prescriber wants you to assess the result.

Match the formulation

Two 2020 trials randomized 1,440 people aged nine or older with moderate or severe facial acne to clascoterone 1% cream or matching vehicle, twice daily for 12 weeks. Median age was 18; this was not a menopause-specific study.¹

The current US Winlevi label approves treatment from age 12.² Check the strength and written directions rather than assuming every product discussed online is the prescription being offered.

Read the absolute benefit

Success required clear or almost-clear skin plus a two-grade improvement. Adjusted rates were 18.4% versus 9.0% in one trial and 20.3% versus 6.5% in the other: additional benefits of 9.4 and 13.8 percentage points. Lesion counts were separate outcomes.¹

Ask how the clinician would judge progress for you. Would the follow-up compare photographs, count inflamed spots in a defined area, or assess the overall pattern? Choose the method before starting so the appointment has something more useful than a recollection of the worst day.

Check the comparison

Missing primary outcomes were estimated under a missing-at-random assumption. Cassiopea funded the trials and manuscript; authors disclosed company employment or paid advisory ties. Other acne medicines were excluded. These trials do not establish superiority to another prescription or lasting clearance after stopping.¹

For the assessment that comes before a prescription, our adult acne guide covers the clinical conversation. Take the names of medicines you have stopped as well as the products you currently use.

Review precautions and cost

The US label directs morning and evening application to dry skin after gentle cleansing. Avoid damaged, eczematous or sunburned skin and limit irritating products. Itching, redness, dryness and burning can occur. Discuss troublesome irritation with the prescriber.²

Topical treatment still has systemic warnings. The label describes suppression of the adrenal hormone-control system, with absorption increased by large treated areas, prolonged use or covering dressings. In a two-week pharmacokinetic study, suppression occurred in 1/20 adults and 2/22 adolescents; all recovered by four weeks after stopping. Adult exposure averaged about six grams twice daily. Those figures do not estimate risk from usual facial use.²

The label also records elevated potassium in some study participants, without requiring routine potassium testing for everyone. Pregnancy and breastfeeding data are unavailable; discuss these circumstances before use.²

The 2024 AAD guideline conditionally recommends clascoterone. It rates the evidence highly but identifies cost and access as reasons for the conditional recommendation.³ Ask the pharmacy for your own out-of-pocket cost before filling it. Ask the prescriber what the plan would be if continued treatment becomes unaffordable.

Skin, Head to Toe discusses clascoterone in “Prescriptions, Neutrally.” Its “Twelve Weeks” section includes a Skin Log for dated products, photographs and irritation. See the book.